Onkológia 2/2017

Criteria of the oncology drugs categorisation process on use of the principle „the value for money“ from the point of view of expected benefits

Purpose: The purpose of this paper was to find out the criteria of the oncology drugs categorisation process on use of the principle „the value for money“ from the point of view of expected benefits. Materials and methods: The basic method used was the general overview of the interest area with illustration by 3 cases from practice, e.g. 3 requests for insertion into list of categorised drugs and assignment the sum of reimbursement. Results: In all 3 cases the expenditures from public health insurance relating to incremental benefit were expressed in QALY and in all cases modeling was used as the method with using comparator. The upper limit of ICER (30 030 € by law 363/2011 Z.z.) did not exceed in any case. Conclusions: Oncologic drugs are evaluated methodically in categorisation process by systematic approach. The recommended methods for use are respected sufficiently. The cost effectiveness is usually based on cost utility analysis.

Keywords: value for money, drugs categorisation, oncology